Image

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

Recruiting
18 - 75 years of age
Both
Phase N/A

Powered by AI

Overview

The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these patients. Using the advance proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. It can be used to get a better treatment response and tumor necrosis before LDLT. As a result, it will improve recurrence-free survival and overall survival rate, especially in high-risk groups. In addition, lenvatinib is approved for using in patients with advanced liver cancer because its overall survival rate is not less than sorafenib in clinical trials. A new generation of targeted therapies will be applied to adjuvant therapy after LDLT.

Eligibility

Inclusion Criteria

  • Targeted therapy is acceptable within 1-2 months after liver transplantation.
  • Immunosuppressive regimen consists of calcineurin inhibitor, mycophenolate mofetil and sirolimus.
  • All male and female participants must take reliable contraceptive measures during the trial and within four weeks after the end of the trial.
  • The definition of high-risk patients:
  • The PET scan is positive before LDLT;
  • Tumors beyond USCF criteria
  • Poorly-differentiated tumor;
  • The patients who has poor AFP response (<15%)or AFP>400 ng/ml after LRT after conventional LRT (RFA态PEI or TACE)

Exclusion Criteria

  • Life expectancy is less than 3 months
  • Patients are with other malignant tumors simultaneously.
  • Patients are anaphylaxis to the inactive ingredients of lenvatinib or drugs.
  • Pregnant or lactating women (Female participants need pregnancy test within 7 days before treatment).
  • Preoperative history of severe cardiovascular disease: congestive heart failure > NYHA grade 2; active coronary heart disease (myocardial infarction occurred within 6 months before entry into the study); severe arrhythmia requiring antiarrhythmic treatment (allowable use of beta-blockers or digoxin); uncontrolled hypertension.
  • History of HIV infection.
  • Severe clinical active infections (> NCI-CTCAE version 3.0).
  • Epilepsy patients requires medication (e.g. steroids or antiepileptic drugs).
  • Patients with kidney diseases requires renal dialysis.
  • Drug abuse, medical symptoms, mental illness or social status that may interfere with participants' participation in research or evaluation of research results.
  • Patients who could not swallow oral drugs, such as those with severe upper gastrointestinal obstruction and need gastric tube feeding.

Study details

High Risk of Recurrence

NCT06327269

Chang Gung Memorial Hospital

1 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.